Moderna Inc said on Monday (November 16) its experimental vaccine was 94.5% effective in preventing COVID-19 based on interim data from a late-stage clinical trial, becoming the second U.S. company in a week to report results that far exceed expectations.

Moderna says its vaccine is 94.5% effective in preventing COVID-19

As the news by top coronavirus vaccine candidate Moderna is creating a lot of buzz, the World Health Organization chief has called it "encouraging", but warned that "complacency" must be avoided.&nbsp;

"This is no time for complacency," WHO chief Tedros Adhanom Ghebreyesus said in a virtual briefing on Monday, as quoted by news agency AFP.&nbsp;

Watch |&nbsp;

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/wion-dispatch-moderna-says-its-covid-19-vaccine-is-over-94-effective-343541/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

"This is a dangerous virus, which can attack every system in the body. Those countries that are letting the virus run unchecked are playing with fire."

Also read |&nbsp;<a href="https://www.wionews.com/world/why-data-from-modernas-experimental-vaccine-is-truly-groundbreaking-343529">Why data from Moderna's experimental vaccine is truly groundbreaking</a>

The pharma company released early results from a clinical trial which included 30,000 participants after Americ's Pfizer and its German partner BioNTech last week said their Covid-19 vaccine was 90 per cent effective.&nbsp;

Earlier, hopes rose on Monday amid Covid-19's grim after news broke that Moderna's vaccine was found to be about 95 per cent effective in a trial.&nbsp;

The pharma company released early results from a clinical trial which included 30,000 participants after America's Pfizer and its German partner BioNTech last week said their Covid-19 vaccine was 90 per cent effective.&nbsp;

"This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease," said Moderna CEO Stephane Bancel.

However, the WHO chief has said that finding the vaccine "will not end the pandemic".

As the news by top coronavirus vaccine candidate Moderna is creating a lot of buzz, the World Health Organization chief has called it "encouraging", but warned that "complacency" must be avoided.

As the news by top coronavirus vaccine candidate Moderna is creating a lot of buzz, the World Health Organization chief has called it "encouraging", but warned that "complacency" must be avoided. "This is no time for complacency," WHO chief Tedros Adhanom Ghebreyesus said in a virtual briefing on Monday, as quoted by news agency AFP. Watch | "This is a dangerous virus, which can attack every system in the body. Those countries that are letting the virus run unchecked are playing with fire." Also read | Why data from Moderna's experimental vaccine is truly groundbreaking The pharma company released early results from a clinical trial which included 30,000 participants after Americ's Pfizer and its German partner BioNTech last week said their Covid-19 vaccine was 90 per cent effective. Earlier, hopes rose on Monday amid Covid-19's grim after news broke that Moderna's vaccine was found to be about 95 per cent effective in a trial. The pharma company released early results from a clinical trial which included 30,000 participants after America's Pfizer and its German partner BioNTech last week said their Covid-19 vaccine was 90 per cent effective. "This positive interim analysis from our Phase 3 study has given us the first clinical validation that our vaccine can prevent COVID-19 disease, including severe disease," said Moderna CEO Stephane Bancel. However, the WHO chief has said that finding the vaccine "will not end the pandemic".

Covid-19 vaccine news 'encouraging', but no time for 'complacency': WHO chief

On Monday, American company Moderna Inc announced a milestone in the development of its experimental COVID-19 vaccine. According to the company, the vaccine is 94.5 per cent effective, the highest claim by any company so far.&nbsp;

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-wion-vaccine-tracker-the-vaccines-that-could-be-approved-first-343049/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

Earlier, Pfizer, another American company had announced that its vaccine is over 90 per cent effective. Following this, countries like Russia and China were quick to claim the same for their national vaccine development programmes.

Moderna’s announcement is actually a very big milestone. Here’s why:

Pfizer’s vaccine requires ultra-cold storage, making its transportation expensive and sometimes logistically impossible, especially for delivery in far off countries, and places with namesake medical facilities.

But Moderna has an advantage, for its vaccine does not require ultra-cold storage, which makes its storage and distribution easier, implying it could reach more people.

Also read:&nbsp;<a href="https://www.wionews.com/world/modernas-covid-19-vaccine-reaches-milestone-with-945-effectiveness-343509" hreflang="en">Moderna's COVID-19 vaccine reaches milestone with 94.5% effectiveness</a>

The company claims that the vaccine will remain stable at standard refrigerator temperature of 2-8 degree Celsius (36-48 degree F) for 30 days. Additionally, the vaccine may be stored for upto 6 months at -20 degrees Celsius.

On the other hand, Pfizer’s vaccine needs to be shipped and stored at -70 degree celsius, akin to the temperatures in Antarctica during winters. In standard refrigeration conditions, it may be stored for upto 5 days.

Very low rate of infection

Moderna’s data is based on analysis of 95 infections among participants in the trial. They received either a placebo or the vaccine.

Out of these, only five infections occurred among people who were inoculated, who were given the vaccine in two shots 28 days apart.

Also read:&nbsp;<a href="http://13.235.153.162/world/a-vaccine-on-its-own-will-not-end-the-pandemic-says-who-chief-343501" hreflang="en">'A vaccine on its own will not end the pandemic', says WHO chief</a>

Additionally, Moderna’s trials witnessed the participation of 30,000 people. And it was able to prevent severe cases of COVID-19, something Pfizer is yet to ascertain with its own vaccine.

Out of the 95 cases during Moderna’s trials, only 11 were severe. All of them occurred among patients who got the placebo. Moderna is part of the US government’s Operation Warp Speed programme, which intends to fast track vaccines for COVID-19, and its earliest deployment.

Just this year, the company intends to produce 20 million doses for the US. Out of these, millions have already been produced.&nbsp;Moderna is ready to ship these vaccines as soon as it received FDA authorisation.

On Monday, American company Moderna Inc announced a milestone in the development of its experimental COVID-19 vaccine. According to the company, the vaccine is 94.

On Monday, American company Moderna Inc announced a milestone in the development of its experimental COVID-19 vaccine. According to the company, the vaccine is 94.5 per cent effective, the highest claim by any company so far. Earlier, Pfizer, another American company had announced that its vaccine is over 90 per cent effective. Following this, countries like Russia and China were quick to claim the same for their national vaccine development programmes. Moderna’s announcement is actually a very big milestone. Here’s why: Pfizer’s vaccine requires ultra-cold storage, making its transportation expensive and sometimes logistically impossible, especially for delivery in far off countries, and places with namesake medical facilities. But Moderna has an advantage, for its vaccine does not require ultra-cold storage, which makes its storage and distribution easier, implying it could reach more people. Also read: Moderna's COVID-19 vaccine reaches milestone with 94.5% effectiveness The company claims that the vaccine will remain stable at standard refrigerator temperature of 2-8 degree Celsius (36-48 degree F) for 30 days. Additionally, the vaccine may be stored for upto 6 months at -20 degrees Celsius. On the other hand, Pfizer’s vaccine needs to be shipped and stored at -70 degree celsius, akin to the temperatures in Antarctica during winters. In standard refrigeration conditions, it may be stored for upto 5 days. Very low rate of infection Moderna’s data is based on analysis of 95 infections among participants in the trial. They received either a placebo or the vaccine. Out of these, only five infections occurred among people who were inoculated, who were given the vaccine in two shots 28 days apart. Also read: 'A vaccine on its own will not end the pandemic', says WHO chief Additionally, Moderna’s trials witnessed the participation of 30,000 people. And it was able to prevent severe cases of COVID-19, something Pfizer is yet to ascertain with its own vaccine. Out of the 95 cases during Moderna’s trials, only 11 were severe. All of them occurred among patients who got the placebo. Moderna is part of the US government’s Operation Warp Speed programme, which intends to fast track vaccines for COVID-19, and its earliest deployment. Just this year, the company intends to produce 20 million doses for the US. Out of these, millions have already been produced. Moderna is ready to ship these vaccines as soon as it received FDA authorisation.

Why data from Moderna's experimental vaccine is truly groundbreaking

Vaccine-maker Moderna Inc will soon apply for real-time reviews of its experimental COVID-19 vaccine in Europe, days after the EU health regulator launched rolling reviews of shots from its rivals.

WION Special Story: 10 months of COVID-19, still no vaccine | World News

In the latest non-human trial for US companies, the Moderna COVID-19 vaccine protected 16 monkeys against COVID-19. Watch report.

Human trials begins for Moderna vaccine: Successful on monkey

moderna-vaccine

Moderna Vaccine, News on Moderna Vaccine, stories on Moderna Vaccine, articles on Moderna Vaccine, Moderna Vaccine stories at Wion, Moderna Vaccine news, Moderna Vaccine latest news

moderna vaccine

Moderna says its vaccine is 94.5% effective in preventing COVID-19

Covid-19 vaccine news 'encouraging', but no time for 'complacency': WHO chief

Why data from Moderna's experimental vaccine is truly groundbreaking

WION Special Story: 10 months of COVID-19, still no vaccine | World News

Human trials begins for Moderna vaccine: Successful on monkey